June 2012, 2:35,
Open Access This content is freely available online to anyone, anywhere at any time.
Date: 27 Jun 2012
The power of FDG-PET to detect treatment effects is increased by glucose correction using a Michaelis constant
We recently showed improved between-subject variability in our [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) experiments using a Michaelis-Menten transport model to calculate the metabolic tumor glucose uptake rate extrapolated to the hypothetical condition of glucose saturation: , where K i is the image-derived FDG uptake rate constant, K M is the half-saturation Michaelis constant, and [glc] is the blood glucose concentration. Compared to measurements of K i alone, or calculations of the scan-time metabolic glucose uptake rate (MRgluc = K i * [glc]) or the glucose-normalized uptake rate (MRgluc = K i*[glc]/(100 mg/dL), we suggested that could offer increased statistical power in treatment studies; here, we confirm this in theory and practice.
We compared K i, MRgluc (both with and without glucose normalization), and as FDG-PET measures of treatment-induced changes in tumor glucose uptake independent of any systemic changes in blood glucose caused either by natural variation or by side effects of drug action. Data from three xenograft models with independent evidence of altered tumor cell glucose uptake were studied and generalized with statistical simulations and mathematical derivations. To obtain representative simulation parameters, we studied the distributions of K i from FDG-PET scans and blood [glucose] values in 66 cohorts of mice (665 individual mice). Treatment effects were simulated by varying and back-calculating the mean K i under the Michaelis-Menten model with K M = 130 mg/dL. This was repeated to represent cases of low, average, and high variability in K i (at a given glucose level) observed among the 66 PET cohorts.
There was excellent agreement between derivations, simulations, and experiments. Even modestly different (20%) blood glucose levels caused K i and especially MRgluc to become unreliable through false positive results while remained unbiased. The greatest benefit occurred when K i measurements (at a given glucose level) had low variability. Even when the power benefit was negligible, the use of carried no statistical penalty. Congruent with theory and simulations, showed in our experiments an average 21% statistical power improvement with respect to MRgluc and 10% with respect to K i (approximately 20% savings in sample size). The results were robust in the face of imprecise blood glucose measurements and K M values.
When evaluating the direct effects of treatment on tumor tissue with FDG-PET, employing a Michaelis-Menten glucose correction factor gives the most statistically powerful results. The well-known alternative ‘correction’, multiplying K i by blood glucose (or normalized blood glucose), appears to be counter-productive in this setting and should be avoided.
Wahl RL, Henry CA, Ethier SP: Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-d-glucose in rodents with mammary carcinoma. Radiology 1992,183(3):643–647.PubMed
Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H: Influence of the blood glucose concentration on FDG uptake in cancer–a PET study. Journal of nuclear medicine: official publication. Soc Nucl Med 1993,34(1):1–6.
Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN: FDG-PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 1998,39(6):1030–1033.PubMed
Torizuka T, Zasadny KR, Wahl RL: Diabetes decreases FDG accumulation in primary lung cancer. Clin Positron Imag Offic J Inst Clin PET 1999,2(5):281–287.CrossRef
Eary JF, Mankoff DA: Tumor metabolic rates in sarcoma using FDG-PET. J Nucl Med Offic Publ, Soc Nucl Med 1998,39(2):250–254.
Crouthamel MC, Kahana JA, Korenchuk S, Zhang SY, Sundaresan G, Eberwein DJ, Brown KK, Kumar R: Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Can Res Offic J Am Assoc Canc Res 2009,15(1):217–225.CrossRef
Gallagher EJ, Fierz Y, Vijayakumar A, Haddad N, Yakar S, Leroith D: Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia. Oncogene 2011.
Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M: The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977,28(5):897–916.PubMedCrossRef
Gottesman I, Mandarino L, Verdonk C, Rizza R, Gerich J: Insulin increases the maximum velocity for glucose uptake without altering the Michaelis constant in man. Evidence that insulin increases glucose uptake merely by providing additional transport sites. J Clin Investig 1982,70(6):1310–1314.PubMedCrossRef
Rivenzon-Segal D, Rushkin E, Polak-Charcon S, Degani H: Glucose transporters and transport kinetics in retinoic acid-differentiated T47D human breast cancer cells. Am J Physiol Endocrinol Metab 2000,279(3):E508-E519.PubMed
Williams SP, Fredrickson J, Mckenzie M, Jones C, Gates M, Hoeflich K, LoRusso P, Rosen L, Sikic B, Ma W, Chan I, de Crespigny AJ: Preclinical and clinical evidence for MEK pathway inhibition by GDC-0973 using FDG-PET. Presentation 1280/5. Proceedings of the American Association for Cancer Research 102nd Annual Meeting: April 2–6 2011; Orlando
McArthur GA, Puzanov I, Ribas A, Chapman PB, Kim KB, Sosman JA: Early FDG-PET responses to PLX4032 in BRAF-mutant advanced melanoma [abstract]. J Clin Oncol 2010, 28:15s.
Carlino MS, Saunders CA, Gebski V, Menzies AM, Ma B, Lebowitz PF: Heterogeneity of FDG-PET response to GSK2118436, an inhibitor of oncogenic mutant BRAF-kinase in BRAF-mutant metastatic melanoma [abstract]. J Clin Oncol 2011., 29:
Flores JE, McFarland LM, Vanderbilt A, Ogasawara AK, Williams SP: The effects of anesthetic agent and carrier gas on blood glucose and tissue uptake in mice undergoing dynamic FDG-PET imaging: sevoflurane and isoflurane compared in air and in oxygen. Mol Imag Biol 2008,10(4):192–200.CrossRef
Hoeflich KP, Herter S, Tien J, Wong L, Berry L, Chan J, O'Brien C, Modrusan Z, Seshagiri S, Lackner M, Stern H, Choo E, Murray L, Friedman L, Belvin M: Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res 2009,69(7):3042–3051.PubMedCrossRef
Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, Friedman L, Lackner M: In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009,15(14):4649–4664.PubMedCrossRef
R Development Core Team: R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2011.
Rice J: Power. Mathematical Statistics and Data Analysis. Belmont: Duxbury Press; 1995.
Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJ, Kotzerke J, Hoekstra OS, Pruim J, Marsden PK, Tatsch K, Hoekstra CJ, Visser EP, Arends B, Verzijlbergen FJ, Zijlstra JM, Comans EF, Lammertsma AA, Paans AM, Willemsen AT, Beyer T, Bockisch A, Schaefer-Prokop C, Delbeke D, Baum RP, Chiti A, Krause BJ: FDG-PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010,37(1):181–200.PubMedCrossRef
Arnold SF: Inferences in Multiple Regression. Mathematical Statistics. NJ: Prentice-Hall; 1990.
Christensen R: Plane Answers to Complex Questions: The Theory of Linear Models. 1st edition. New York: Springer; 1987.
- The power of FDG-PET to detect treatment effects is increased by glucose correction using a Michaelis constant
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
- Online Date
- June 2012
- Online ISSN
- Additional Links
- Glucose correction
- Response to treatment
- Glucose bias
- Author Affiliations
- 1. Department of Biomedical Imaging, Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA
- 2. Department of Pharmacokinetics and Pharmacodynamics, Genentech, Inc., South San Francisco, CA, 94080, USA
- 3. Department of Biostatistics, Genentech, Inc., South San Francisco, CA, 94080, USA